RCC, weakly expressed in clear-cell RCC and negatively expressed in papillary RCC.
AB138. Experience on thulium laser treatment in transurethral resection of bladder tumor

Xiuguo Gan, Ruihua An
Harbin Medical University, Harbin 150081, China Objective: To study the safety and efficacy of thulium laser treatment of bladder cancer. Methods: Thulium laser surgery system was used for the treatment of 45 cases of bladder cancer patients, including 33 cases of single tumor, 12 cases of multiple tumors. Tumor diameter were 5-25 mm. Tumor pathology were bladder transitional cell carcinoma, clinical stage at T1-T2. Results: All the surgery was successfully completion. Operation time was 10-35 minutes. Blood loss was 0-5 mL. None of bladder has perforation, water intoxication, urinary leakage or postoperative bleeding. All of the patients had received immediate intravesical chemotherapy within 0.5 hours, and to maintain bladder chemotherapy. All had catheter indwelled 5 to 7 days. Patients were followed up 1 year, no recurrence of the surgical area. Conclusions: Thulium laser surgery system for the transurethral treatment of bladder cancer within stage T2 is safe and effective. Objective: To investigate whether low-dose BCG treatment can reduce the side effects while maintaining efficacy for patients with NMIBC when compared with standard dose BCG treatment. Methods: A comprehensive literature search of PubMed, EMBASE, CINAHL, LILACS and CENTRAL databases was conducted to identify relevant randomized controlled trials (RCT) or quasi-randomized controlled trials (qRCT) that have assessed the efficacy of low and standard dose BCG therapy for patients with NMIBC. Systematic review and meta-analysis were performed according to preferred reporting items for systematic reviews and meta-analysis criteria. Results: Six RCTs and two qRCTs were eligible for metaanalysis. Low-dose BCG instillation was not inferior to reduce the risk of bladder tumor recurrence [hazard ratio (HR), 1.15; 95% confidence interval (CI), 1.00-1.31; P=0.05], meanwhile no difference was found regarding tumor progression (HR =1.08; 95% CI, 0.83-1.42; P=0.57). However, low-dose BCG provided a significantly lower incidence of overall side effects (RR =0.75; 95% CI,
